Evommune (NYSE:EVMN) Trading Down 6.9% – Time to Sell?

Posted by Stanley Muller on Aug 22nd, 2026

Evommune, Inc. (NYSE:EVMN – Get Free Report) traded down 6.9% on Thursday . The stock traded as low as $14.37 and last traded at $13.9810. 12,789 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 630,046 shares. The stock had previously closed at $15.01.

Analyst Ratings Changes

EVMN has been the subject of a number of recent research reports. Stifel Nicolaus initiated coverage on Evommune in a report on Friday, May 1st. They set a “buy” rating and a $54.00 price objective for the company. William Blair lowered Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. Weiss Ratings cut Evommune from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. HC Wainwright reissued a “neutral” rating on shares of Evommune in a research report on Monday, August 3rd. Finally, Morgan Stanley dropped their price objective on Evommune from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Evommune presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

Check Out Our Latest Stock Report on Evommune

Evommune Stock Up 2.4%

The company’s 50-day moving average is $14.75 and its two-hundred day moving average is $20.83. The company has a market cap of $504.07 million and a P/E ratio of -1.26.

Evommune (NYSE:EVMN – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). On average, analysts anticipate that Evommune, Inc. will post -3.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jeegar Pravinkumar Patel sold 1,488 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $22.50, for a total transaction of $33,480.00. Following the completion of the transaction, the insider owned 46,403 shares in the company, valued at approximately $1,044,067.50. This represents a 3.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Luis C. Pena sold 7,438 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $22.71, for a total value of $168,916.98. Following the transaction, the chief executive officer owned 630,458 shares of the company’s stock, valued at $14,317,701.18. The trade was a 1.17% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 100,854 shares of company stock valued at $2,279,142. Company insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Evommune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVMN. EQT Fund Management S.a r.l. bought a new stake in shares of Evommune in the fourth quarter valued at approximately $84,395,000. RA Capital Management L.P. bought a new position in Evommune in the 4th quarter worth approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC purchased a new position in Evommune in the 4th quarter valued at approximately $32,989,000. Nan Fung Group Holdings Ltd bought a new stake in Evommune during the 4th quarter valued at $24,670,000. Finally, JPMorgan Chase & Co. bought a new stake in Evommune during the 4th quarter valued at $22,408,000.

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.